In recent years, the proportion of biological drugs in the global pharmaceutical market has been close to 20%. The focus within the global pharmaceutical market has been gradually shifting from small molecule chemical drugs to biomacromolecules (biological drugs). It also appears that the trend is gradually expanding. Biological drugs are a broad class of pharmaceuticals generated by using principles and methods of biology, immunology, physical chemistry, and pharmacology, etc. These drugs utilize the composition of various organisms and biological tissues, as well as organs. Biological drugs usually include genetic engineering drugs, antibody engineering drugs, blood products drugs, and vaccines etc. Among these, antibody drugs are one of the fastest growing human therapeutic drugs. This increase in research and development has proved to be an effective treatment for many important diseases such as cancer, chronic inflammatory diseases, cardiovascular diseases, immune system diseases, and infectious diseases. The antibody research and development also plays an important role in medicine and diagnostics.
Synbio Technologies’ Antibody Platform utilizes molecular simulation technologies to provide antibody de novo design and preparation services. We use this platform to simulate various biological behaviors of antibody molecules on the atomic level. We can analyze the antibody structure as a starting point to solve a series of problems such as the theoretical design of an antibody. The combination of the molecular simulation technology and experimental approach can help our customers effectively reduce the total cost of antibody R&D to effectively shorten the R&D cycle.
Featured Advantages
- Powerful drug-like antibody bio-computation
- Cloud computing
- Supercomputing
- Facilitate the development of “biologically superior” antibody drugs
- Antibodies humanization
- Affinity maturation
- Full human antibody library design
- Proprietary software platforms
- High-throughput antibody modeling
- Effective antigen-antibody docking
- Therapeutic antibodies have been licensed
Service flow
Synbio Technologies’ Case Study
1. Methods of constructing antibody library
- Extracted the H1, H2, H3, L1, L2 and L3 regions of the antibody from the PDB database
- Created CDRs library
- Created germline
- Assembled the CDR into the germline template
- Created a complete antibody structure
2. Screening antibodies with specific antigens
- Docked antigens with the antibody library
- Sorted optimized antibodies based on interaction energy
- Selected the best antibody based on evaluation
- Antibody affinity modification
- Synthesized the first 100 antibody sequences
3. Structural modeling method
- Searched template
- Constructed an antibody backbone
- Constructed the side chain of target protein
- Constructed loop region
- Final optimization of structure
4. Synbio Technologies’ antibody library model
5. Results
Figure 1. Anti-antibody complex structure predicted by Synbio Technologies (the epitope is similar to the crystal structure of Figure 2)
Figure 2. Crystal structure of the antigen-antibody complex from the PDB database
6. Final data
Designed 1~100 antibody sequences for antigen, all affinities were greater than 10-10M.
Statistical table of affinity test results
Service Specifications
* Customers can provide the antigen name or gene ID directly; If you have antigen crystal structure, please contact us directly.